Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Supernus, Inc. - Common Stock (NQ:SUPN)

28.21 UNCHANGED
Delayed Quote Updated: 4:00 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Supernus, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
US Top Movers: Small-Cap Gainers and Losers in Today's Session ↗
Via Chartmill
US Top Movers: Gainers and Losers for Nov. 3, 2026 ↗
Via Chartmill
US Stock Gap Movers: Up and Down Names in Today's Session ↗
Via Chartmill
Premarket Movers: Gainers and Losers Ahead of November 3, 2026 U.S. Open ↗
Via Chartmill
Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q3 Estimates and Raises Outlook as Indivior Merger Nears ↗
Via Chartmill
News headline image
SUPN Q3 deep dive: robust portfolio growth and integration priorities amid Indivior merger
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) announced better-than-expected revenue in Q3 2026, with sales up 18.1% year on year t... 
Via StockStory
News headline image
Supernus (SUPN) Q3 2026 Earnings Call Transcript ↗
Qelbree prescriptions surged 18% as revenue hit $226.8 million ahead of Indivior merger. 
Via The Motley Fool
Topics Earnings
News headline image
Supernus Pharmaceuticals Q3 Earnings Call Highlights ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is... 
Via MarketBeat
Topics Earnings
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) delivers impressive Q3 2026, full-year sales guidance is optimistic
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) beat Wall Street’s revenue expectations in Q3 2026, with revenue rising 18.1% year on... 
Via StockStory
News headline image
Supernus Pharmaceuticals earnings: what to look for from SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be announcing earnings results this Thursday after market hours. Here’s what to ... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Russell 2000 Stock with Exciting Potential and 2 We Ignore
Small-cap stocks in the Russell 2000 (^RUT) can be a goldmine for investors looking beyond the usual large-cap names. But with less stability and fewer resou... 
Via StockStory
Topics Supply Chain
News headline image
1 Healthcare Stock Worth Your Attention and 2 We Turn Down
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Those leading the charge have not on... 
Via StockStory
News headline image
1 Unprofitable Stock with Impressive Fundamentals and 2 We Avoid
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Question
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Topics Credit Cards
News headline image
3 Reasons SUPN is Risky and 1 Stock to Buy Instead
Over the last six months, Supernus Pharmaceuticals’s shares have sunk to $41.99, producing a disappointing 14.7% loss - a stark contrast to the S&P 500’s 16.... 
Via StockStory
Topics Stocks Supply Chain
News headline image
Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)
Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Supernus Pharmaceuticals (NAS... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
3 Cash-Heavy Stocks Walking a Fine Line
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face c... 
Via StockStory
News headline image
1 of Wall Street’s Favorite Stocks with Promising Prospects and 2 Facing Headwinds
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
3 Out-of-Favor Stocks We’re Skeptical Of
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether... 
Via StockStory
News headline image
3 Small-Cap Stocks with Open Questions
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that ... 
Via StockStory
News headline image
1 Healthcare Stock with Exciting Potential and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
Topics Retirement
News headline image
Supernus Pharmaceuticals Reports Q2 2026 Results: Full Earnings Call Transcript ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) held its second-quarter earnings conference call on Tuesday. Below is the complete transcript from the call. This transcript is brought to you by Benzinga APIs.... 
Via Benzinga
Topics Earnings
News headline image
3 Russell 2000 Stocks We Approach with Caution
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size ... 
Via StockStory
News headline image
Why Supernus Pharmaceuticals Stock Topped the Market Today ↗
It's effecting a "merger of equals" with a peer. 
Via The Motley Fool
News headline image
Supernus Pharmaceuticals Q2 Earnings Call Highlights ↗
Supernus Pharmaceuticals (NASDAQ:SUPN) and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical... 
Via MarketBeat
Topics Earnings
What's going on in today's pre-market session ↗
Via Chartmill
News headline image
Supernus Pharmaceuticals (NASDAQ:SUPN) Surprises With Q2 CY2026 Sales, Stock Jumps 24.9%
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 3... 
Via StockStory
News headline image
Supernus Pharmaceuticals Earnings: What To Look For From SUPN
Specialty pharmaceutical company Supernus Pharmaceuticals (NASDAQ:SUPN) will be reporting results this Tuesday after market hours. Here’s what to look for. S... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock on Our Buy List and 2 That Underwhelm
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
1 Growth Stock to Stash and 2 We Turn Down
Growth is oxygen. But when it evaporates, the consequences can be severe - ask anyone who bought Cisco in the Dot-Com Bubble or newer investors who lived thr... 
Via StockStory
Topics Artificial Intelligence
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.